PCSK9抑制剂对血脂代谢及心血管功能作用的研究进展  

The researches of PCSK9 inhibitors on lipid metabolism and cardiovascular function

作　　者：丁怀玉[1] 黄榕翀 DING Huai-yu;HUANG Rong-chong(Department of Cardiology, the First Affiliated Hospital of Dalian Medical University,Liaoning,Dalian 116011,China;Department of Cardiology, Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China)

机构地区：[1]大连医科大学附属第一医院心内科,辽宁大连116011 [2]首都医科大学附属北京友谊医院心内科,北京100050

出　　处：《中国医学前沿杂志（电子版）》2019年第5期12-14,共3页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

基　　金：国家自然科学基金(81770340);辽宁省高等学校基本科研项目青年基金(LQ2017020)

摘　　要：高脂血症是公认的心血管病的重要危险因素。尽管目前有他汀类、贝特类等较多调脂药物,但仍然有很多患者血脂控制不佳。近年研究发现,前蛋白转化酶枯草溶菌素9/kexin 9型(proprotein convertase subtilisin/kexin type 9,PCSK9)抑制剂可有效降低血浆胆固醇水平,并且可能改善心血管病预后。本文就PCSK9抑制剂对血脂代谢和心血管功能的影响进行讨论。Hyperlipidemia is a well-established risk factor for cardiovascular disease. Although there are several developed lipid lowering drugs such as statins and fenofibrates, many patients do not achieve an adequate response. Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been developed as a new therapeutic strategy for cholesterol regulation, and could exert beneficial effects on cardiovascular disease outcomes. This review discusses the effects of PCSK9 inhibitors on lipid metabolism and cardiovascular function.

关 键 词：PCSK9抑制剂 高脂血症 低密度脂蛋白胆固醇 

分 类 号：R589.2[医药卫生—内分泌]